Group 1 - Enwei Pharmaceutical (301331.SZ) released its semi-annual report for 2025, indicating that as of August 25, 2025, 11 institutional investors held a total of 73.5785 million shares, accounting for 71.51% of the total share capital [1] - The top ten institutional investors collectively held 71.13% of the shares, with a slight decrease of 0.22 percentage points compared to the previous quarter [1] - One public fund, Rongtong Health Industry Flexible Allocation Mixed A/B, reported a decrease in holdings by 0.46% compared to the previous quarter [1] Group 2 - One new foreign institutional investor disclosed during this period is China International Capital Corporation Hong Kong Asset Management Limited - CICCFT10(Q) [2]

Core Viewpoint - Enwei Pharmaceutical Co., Ltd. held its seventh meeting of the third board of directors on August 25, 2025, where several important resolutions were passed, indicating the company's commitment to transparency and compliance with regulations [1][2][3]. Summary by Relevant Sections Meeting Details - The meeting was conducted both in-person and via communication, with all 8 directors present, and was chaired by Chairman Xue Yongjiang, complying with the Company Law and Articles of Association [1]. Resolutions Passed - The 2025 Semi-Annual Report and its summary were approved, confirming that the report adheres to accounting standards and accurately reflects the company's operational status for the first half of 2025, with a unanimous vote of 8 in favor [2]. - A special report on the storage and use of raised funds was approved, indicating that the company has complied with regulations regarding the management of these funds, also receiving a unanimous vote of 8 in favor [2]. - The proposal for the extension of certain fundraising investment projects was approved, deemed a prudent decision aligned with the company's long-term development strategy, again with a unanimous vote of 8 in favor [2]. Future Implications - The resolutions from this meeting are expected to significantly impact the future development of Enwei Pharmaceutical, prompting investors to closely monitor the company's subsequent activities [3].

格隆汇8月25日丨恩威医药(301331.SZ)公布2025年半年度报告，上半年公司实现营业收入4.49亿元，同 比增长15.73%；归属于上市公司股东的净利润3834.42万元，同比增长113.80%；归属于上市公司股东的 扣除非经常性损益的净利润3527.57万元，同比增长132.47%；基本每股收益0.3845元。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-035 恩威医药股份有限公司 第三届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 恩威医药股份有限公司（以下简称"公司"）第三届董事会第七次会议于 2025 年 8 月 25 日以现场及通讯方式召开。本次会议通知于 2025 年 8 月 15 日以通讯 方式发出，本次会议应出席董事 8 人，实际出席董事 8 人，会议由董事长薛永江 先生主持。本次会议的召开符合《公司法》和《公司章程》的有关规定，所做决 议合法有效。 二、董事会会议审议情况 1、审议通过《2025 年半年度报告及其摘要》 同意《恩威医药股份有限公司 2025 年半年度报告及其摘要》，报告编制符 合企业会计准则及相关法律、法规、规章及规范性文件的要求，真实、准确、完 整地反映了公司 2025 年半年度经营状况，不存在虚假记载、误导性陈述和重大 遗漏。 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》以及《募集资金使用管理办法》等规定和要求，存放和使用募 ...

中信证券股份有限公司 关于恩威医药股份有限公司 部分募集资金投资项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）担任恩威医 药股份有限公司（以下简称"恩威医药"、"上市公司"或"公司"）首次公开发 行股票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《上市公司募集资金监管规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交 易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对恩威医药部 分募集资金投资项目延期的事项进行了审慎的核查，具体情况如下： 一、本次募集资金的基本情况 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，每股面 值 1.00 元，发行价格为人民币 29.80 元/股。本次募集资金总额为人民币 522,692,000.00 元，扣除发行费用（不含增值税）人民币 79,741,650 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=First%20Section%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides essential disclaimers, a report directory, and definitions of key terms to ensure clear understanding of the report content [Important Notice](index=2&type=section&id=Important%20Notice) The company's board of directors, directors, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content - The company's board of directors, directors, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, with no false records, misleading statements, or major omissions[4](index=4&type=chunk) - The company may face risks such as industry policy changes, market risks, cost fluctuation risks, R&D innovation risks, and goodwill impairment risks, detailed in "Section III, X. Risks Faced by the Company and Countermeasures" of this report[5](index=5&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[6](index=6&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section provides definitions for common terms used in the report, including company names, shareholders, subsidiaries, industry standards, and the reporting period Partial Definitions | Term | Definition | | :--- | :--- | | Company, the Company, Joint Stock Company, Enwei Pharmaceutical | Enwei Pharmaceutical Co., Ltd. | | Enwei Group | Chengdu Enwei Investment (Group) Co., Ltd., the controlling shareholder of the Company | | Enwei Pharmaceutical | Sichuan Enwei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company | | GMP | Good Manufacturing Practice (Pharmaceutical Production Quality Management Standards) | | Reporting Period | January 1, 2025 to June 30, 2025 | [Company Profile and Key Financial Indicators](index=6&type=section&id=Second%20Section%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's basic information and a summary of its key financial performance and position during the reporting period [Company Profile](index=6&type=section&id=I.%20Company%20Profile) This section introduces Enwei Pharmaceutical Co., Ltd.'s basic information, including stock details, company names, legal representative, and contact information for key personnel Company Basic Information | Stock Abbreviation | Stock Code | Stock Exchange | Company's Chinese Name | Company's Legal Representative | | :--- | :--- | :--- | :--- | :--- | | Enwei Pharmaceutical | 301331 | Shenzhen Stock Exchange | Enwei Pharmaceutical Co., Ltd. | Xue Yongjiang | Contact Information | Position | Name | Phone | | :--- | :--- | :--- | | Board Secretary | Hu Dawei | 028-85887067 | | Securities Affairs Representative | Tan Yongbao | 028-85887067 | [Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company's operating revenue increased by 15.73%, net profit attributable to shareholders surged by 113.80%, and total assets and net assets also grew Key Accounting Data and Financial Indicators (Year-on-Year Change) | Indicator | Current Reporting Period (yuan) | Prior Period (yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 449,221,452.75 | 388,149,545.27 | 15.73% | | Net Profit Attributable to Shareholders of Listed Company | 38,344,181.25 | 17,934,442.73 | 113.80% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | 35,275,716.98 | 15,174,473.86 | 132.47% | | Net Cash Flow from Operating Activities | 75,182,160.82 | 90,270,973.06 | -16.72% | | Basic Earnings Per Share (yuan/share) | 0.3845 | 0.1769 | 117.35% | | Diluted Earnings Per Share (yuan/share) | 0.3838 | 0.1760 | 118.07% | | Weighted Average Return on Net Assets | 3.57% | 1.66% | 1.91% | Period-End Asset and Liability Data (Year-on-Year Change) | Indicator | End of Current Reporting Period (yuan) | End of Prior Year (yuan) | Change from Prior Year-End | | :--- | :--- | :--- | :--- | | Total Assets | 1,515,984,797.29 | 1,504,528,918.05 | 0.76% | | Net Assets Attributable to Shareholders of Listed Company | 1,082,879,036.14 | 1,057,671,083.49 | 2.38% | [Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) This section lists non-recurring gains and losses affecting the company's profit during the reporting period, totaling 3,068,464.27 yuan, primarily from government grants and fair value changes of financial assets Non-Recurring Gains and Losses Items and Amounts | Item | Amount (yuan) | | :--- | :--- | | Gains and Losses from Disposal of Non-Current Assets | -371,840.37 | | Government Grants Recognized in Current Profit and Loss | 1,707,535.87 | | Gains and Losses from Changes in Fair Value of Financial Assets and Liabilities Held by Non-Financial Enterprises, and from Disposal of Financial Assets and Liabilities, Excluding Effective Hedge Accounting Related to Normal Business Operations | 2,375,001.16 | | Other Non-Operating Income and Expenses Apart from the Above Items | -63,399.60 | | Less: Income Tax Impact | 578,832.79 | | Total | 3,068,464.27 | [Management Discussion and Analysis](index=9&type=section&id=Third%20Section%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's business operations, financial performance, and future outlook, including industry trends and risk factors [Company's Main Business Activities During the Reporting Period](index=9&type=section&id=I.%20Company%27s%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company primarily engages in R&D, production, and sales of traditional Chinese medicine, chemical drugs, and personal care products, focusing on gynecology, pediatrics, respiratory, and health private care sectors [Industry Overview](index=9&type=section&id=%28I%29%20Industry%20Overview) The company operates in the pharmaceutical manufacturing industry (C27), which faces short-term pressure but has positive long-term prospects, supported by national policies for traditional Chinese medicine and digital transformation - The company operates in the pharmaceutical manufacturing industry (industry code "C27"), which has positive long-term development prospects but also faces some short-term pressure[29](index=29&type=chunk) Key Data for Pharmaceutical Manufacturing Industry in H1 2025 | Indicator | Amount/Growth Rate | | :--- | :--- | | Industrial Added Value of Pharmaceutical Manufacturing Enterprises Above Designated Size | Increased by 1.3% YoY | | Operating Revenue | RMB 1,227.52 billion, decreased by 1.2% YoY | | Operating Cost | RMB 715.37 billion, decreased by 0.1% YoY | | Total Profit | RMB 176.69 billion, decreased by 2.8% YoY | | Per Capita Healthcare Consumption Expenditure | 1,314 yuan, increased by 3.4% | | Healthcare Consumer Price Index | Increased by 0.3% YoY | | Traditional Chinese Medicine Sub-category Consumer Price Index | Increased by 0.3% YoY | - National policies continue to support the improvement of traditional Chinese medicine quality, the digital and intelligent transformation of the pharmaceutical industry, and the high-quality development of innovative drugs[30](index=30&type=chunk)[31](index=31&type=chunk) [Main Business and Key Products](index=9&type=section&id=%28II%29%20Main%20Business%20and%20Key%20Products) The company's main business involves R&D, production, and sales of traditional Chinese medicine, chemical drugs, and health personal care products, with "Jieeryin Lotion" as its core product and a diverse portfolio of 21 exclusive varieties - The company primarily engages in the R&D, production, and sales of traditional Chinese medicine, chemical drugs, and health personal care products, focusing on gynecological products, pediatric medications, respiratory system medications, and health personal care products[32](index=32&type=chunk) - The gynecological external lotion “Jieeryin Lotion” is the company's core product, and the company has also developed other dosage forms such as ointments, suppositories, capsules, effervescent tablets, and antiseptic lotions[32](index=32&type=chunk) - The company currently possesses **21 exclusive varieties**, including Jieeryin Lotion, Jianer Pills, and Shanmai Jianpi Oral Liquid[32](index=32&type=chunk) Functions or Uses of Some Key Products on Sale | Category | Product Name | Product Function or Use | OTC/Prescription Drug | Exclusive Variety | | :--- | :--- | :--- | :--- | :--- | | Gynecological Medication | Jieeryin Lotion | Clears heat, dries dampness, kills parasites, and relieves itching; primarily treats damp-heat leukorrhea in women and certain skin diseases | OTC | Yes | | Pediatric Medication | Shanmai Jianpi Oral Liquid | Aids digestion, strengthens spleen, regulates qi, and harmonizes stomach; used for infantile anorexia caused by food stagnation | OTC | Yes | | Respiratory Medication | Huoxiang Zhengqi Oral Liquid | Relieves exterior symptoms, resolves dampness, regulates qi, and harmonizes the middle; used for summer-dampness common cold | OTC | No | | Other | Jinzhi Jieyin Mouthwash | Clears heat, detoxifies, reduces swelling, and relieves pain; suitable for alleviating swelling and pain caused by gingival, periodontal, and mucosal inflammation | OTC | Yes | [Market Position of Key Products](index=13&type=section&id=%28III%29%20Market%20Position%20of%20Key%20Products) The company's core product, "Jieeryin Lotion," consistently ranks first in the Chinese urban retail pharmacy market for gynecological traditional Chinese medicine in the "inflammation sub-category," with other products also holding leading positions - “Jieeryin Lotion” has consistently ranked first in market share for the "inflammation sub-category" of gynecological traditional Chinese medicine in Chinese urban retail pharmacies for many years, and continued to top the "Urban Physical Pharmacy Terminal Gynecological Traditional Chinese Medicine Brand List" in Q1 2025[37](index=37&type=chunk) - “Huaji Oral Liquid” was awarded sixth place in the 2024 China Non-Prescription Drug Traditional Chinese Medicine - Pediatric Digestive Category by the China Non-Prescription Drug Association, and ranked eighth in market share for pediatric anorexia traditional Chinese medicine in Chinese urban physical pharmacies in Q1 2025[38](index=38&type=chunk) - “Compound Yinqiao Amin Capsule” has maintained its number one market share in the compound Yinqiao Amin capsule category in Chinese urban physical pharmacies for several consecutive years as of Q1 2025[39](index=39&type=chunk) [Main Business Model](index=14&type=section&id=%28IV%29%20Main%20Business%20Model) The company primarily uses a "purchase-to-production" model for procurement and "production-to-sales" for manufacturing, with sales mainly through distribution, supplemented by direct sales and a rapidly growing e-commerce channel, which now accounts for approximately 38% of total revenue - The company adopts a "purchase-to-production" model for raw material procurement for its self-produced medicines, conducted through a qualified supplier list and inquiry process[42](index=42&type=chunk) - The company's products primarily adopt an "order-driven production" self-manufacturing model, with a complete production system established in strict accordance with GMP requirements[44](index=44&type=chunk) - The company primarily uses a distribution model, while also expanding channels through direct sales and internet sales (B2B and B2C), with e-commerce sales rapidly increasing to approximately **38% of total sales revenue** by the end of this reporting period[46](index=46&type=chunk) [Analysis of Core Competencies](index=16&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core strengths include strong brand influence ("Jieeryin"), a diversified product portfolio with 21 exclusive varieties, a nationwide omni-channel marketing network, robust supply chain and quality management, and an experienced management team [Brand Advantage](index=16&type=section&id=%28I%29%20Brand%20Advantage) The "Jieeryin" brand, operating for 39 years, enjoys high consumer trust, with its core product "Jieeryin Lotion" consistently ranking first in market share, forming a six-brand matrix under the "Enwei" parent brand - The "Jieeryin" brand has been operating for 39 years, with its core product "Jieeryin Lotion" accumulating over **700 million bottles in sales** and consistently ranking first in market share in the gynecological traditional Chinese medicine sector of Chinese urban retail pharmacies for many years[48](index=48&type=chunk) - The company has established a six-brand matrix with "Enwei" as the parent brand, encompassing "Jieeryin" (gynecological external and personal care non-drug products), "Zhongzhou" (traditional Chinese medicine), "Likeshui" (respiratory system medication), "Haowayou" (pediatric medication), and "Koubao" (oral medication)[50](index=50&type=chunk)[51](index=51&type=chunk) [Product Advantage](index=16&type=section&id=%28II%29%20Product%20Advantage) Through the acquisition of Henan Xinxin Pharmaceutical, the company significantly expanded its product pipeline, now holding 176 drug approval numbers across 16 major areas, including 21 exclusive varieties, with non-drug product sales growing over 100% for three consecutive years - Through the acquisition of Henan Xinxin Pharmaceutical, the company now holds **176 drug approval numbers**, covering 16 major areas such including gynecology, pediatrics, and respiratory, with **21 exclusive varieties**[52](index=52&type=chunk) - The "Jieeryin" non-drug product line has expanded from pharmaceuticals to health care, now covering a full range from female to male personal care, creating multiple best-selling products with sales revenue growing over **100% for three consecutive years** from 2022-2024[54](index=54&type=chunk) [Channel Advantage](index=17&type=section&id=%28III%29%20Channel%20Advantage) The company has established a nationwide omni-channel marketing network covering 31 provinces, collaborating with over 2,200 commercial companies and 1,000 retail chains, with e-commerce sales growing from 19% in 2022 to approximately 38% of total revenue by the end of the reporting period - The company has established a comprehensive modern marketing network system covering 31 provinces, municipalities, and autonomous regions nationwide, with close partnerships with over **2,200 large and medium-sized domestic commercial companies** and **1,000 regional quality chain retail enterprises**[55](index=55&type=chunk)[56](index=56&type=chunk) - The company's e-commerce division has a professional team of over **140 people**, with operations covering mainstream e-commerce platforms such as Ali Health, JD Pharmacy, Pinduoduo, Douyin, Kuaishou, and Xiaohongshu[56](index=56&type=chunk) - The proportion of e-commerce sales in the company's total revenue increased from approximately **19% in 2022** to about **38% by the end of this reporting period**, becoming a significant sales channel for the company[56](index=56&type=chunk) [Supply Chain and Quality Advantage](index=17&type=section&id=%28IV%29%20Supply%20Chain%20and%20Quality%20Advantage) The company adheres to a "full participation, continuous improvement, sustained innovation, meeting demand, benefiting humanity" quality policy, maintaining a robust traditional Chinese medicine manufacturing and quality management system across its Chengdu, Jiangxi, and Henan production bases, with ongoing intelligent production line upgrades - The company has established a comprehensive traditional Chinese medicine manufacturing technology system and quality management system, adhering to the quality policy of "full participation, continuous improvement, sustained innovation, meeting demand, benefiting humanity"[58](index=58&type=chunk) - The company possesses two major production bases in Chengdu and Jiangxi, along with a contract manufacturing base in Henan, demonstrating strong product conversion and output capabilities, with ongoing upgrades to some intelligent production lines[59](index=59&type=chunk)[61](index=61&type=chunk) - The company maintains stable supply chain relationships with upstream raw material suppliers, fully ensuring the supply of necessary raw materials for its products[61](index=61&type=chunk) [Team Advantage](index=18&type=section&id=%28V%29%20Team%20Advantage) The company's management team is highly experienced, led by Chairman and CEO Xue Yongjiang with nearly 30 years in the pharmaceutical industry, ensuring stable development through their deep understanding of industry policies and market trends - Mr. Xue Yongjiang, the company's Chairman and CEO, possesses nearly **30 years of experience** in the pharmaceutical industry and corporate management, demonstrating keen business acumen[62](index=62&type=chunk) - Other members of the management team have a reasonable age structure, generally possess innovative management and continuous learning mindsets, deeply understand pharmaceutical industry policies and market development trends, and have extensive experience in pharmaceutical industry management[62](index=62&type=chunk) [Main Business Analysis](index=18&type=section&id=III.%20Main%20Business%20Analysis) During the reporting period, the company's operating revenue increased by 15.73%, and net profit attributable to shareholders surged by 113.80%, though pediatric product revenue declined, and financial expenses rose due to increased borrowing costs Key Financial Data Year-on-Year Changes | Item | Current Reporting Period (yuan) | Prior Period (yuan) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 449,221,452.75 | 388,149,545.27 | 15.73% | | | Net Profit Attributable to Shareholders of Listed Company | 38,344,181.25 | 17,934,442.73 | 113.80% | | | Financial Expenses | 305,490.34 | -363,864.47 | 183.96% | Primarily due to increased interest expenses on borrowings | | R&D Investment | 2,538,865.32 | 3,367,770.05 | -24.61% | | | Net Cash Flow from Operating Activities | 75,182,160.82 | 90,270,973.06 | -16.72% | | | Net Cash Flow from Investing Activities | -38,767,462.92 | 30,785,409.38 | -225.93% | Primarily due to increased purchases of wealth management products | | Net Cash Flow from Financing Activities | -25,580,789.63 | 96,539,637.29 | -126.50% | Primarily due to new bank loans in the prior period | Products or Services Accounting for Over 10% of Revenue | By Product or Service | Operating Revenue (yuan) | YoY Change in Operating Revenue | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | | Gynecological Products | 207,591,584.00 | 11.73% | -1.55% | | Pediatric Products | 31,010,284.11 | -26.16% | -3.57% | | Cold & Flu Products | 66,058,252.65 | 6.35% | -9.98% | | Other | 142,588,409.62 | 48.78% | 0.63% | [Non-Core Business Analysis](index=19&type=section&id=IV.%20Non-Core%20Business%20Analysis) Non-core business activities positively impacted total profit during the reporting period, with investment income and government grants being the main contributors, while credit impairment losses and asset disposal losses had negative effects Non-Core Business Items and Their Proportion to Total Profit | Item | Amount (yuan) | Proportion of Total Profit | | :--- | :--- | :--- | | Investment Income | 2,818,800.74 | 6.16% | | Asset Impairment | 1,948,506.26 | 4.26% | | Non-Operating Income | 41,133.13 | 0.09% | | Credit Impairment | -1,278,804.58 | -2.80% | | Other Income | 1,707,535.87 | 3.73% | | Gains from Asset Disposal | -263,274.66 | -0.58% | [Analysis of Assets and Liabilities](index=19&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) At the end of the reporting period, total assets and net assets attributable to shareholders increased, with a significant rise in accounts receivable and construction in progress, while contract liabilities and long-term borrowings slightly decreased Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (yuan) | Proportion of Total Assets | Amount at Prior Year-End (yuan) | Proportion of Total Assets | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 360,090,734.90 | 23.75% | 370,274,493.59 | 24.61% | -0.86% | | Accounts Receivable | 171,275,324.36 | 11.30% | 120,242,245.29 | 7.99% | 3.31% | | Inventories | 112,890,172.33 | 7.45% | 115,551,553.67 | 7.68% | -0.23% | | Construction in Progress | 54,845,564.79 | 3.62% | 40,367,890.07 | 2.68% | 0.94% | | Contract Liabilities | 16,942,282.77 | 1.12% | 24,611,986.13 | 1.64% | -0.52% | | Long-Term Borrowings | 180,000,000.00 | 11.87% | 185,000,000.00 | 12.30% | -0.43% | Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (yuan) | Amount Purchased in Current Period (yuan) | Ending Balance (yuan) | | :--- | :--- | :--- | :--- | | Financial Assets Held for Trading | 144,723,359.65 | 870,010,100.00 | 174,983,535.19 | | Other Debt Investments | 176,286,463.60 | | 110,157,392.47 | | Subtotal of Financial Assets | 321,009,823.25 | 870,010,100.00 | 285,140,927.66 | [Analysis of Investment Status](index=20&type=section&id=VI.%20Analysis%20of%20Investment%20Status) The company had no significant equity or non-equity investments during the reporting period, with raised funds totaling RMB 255.4191 million invested in committed projects, and some idle funds used for cash management, while the "Sichuan Enwei Expansion Project" was extended to December 31, 2026 [Overall Use of Raised Funds](index=21&type=section&id=%281%29%20Overall%20Use%20of%20Raised%20Funds) The company's net proceeds from its initial public offering were RMB 442.9503 million, with RMB 32.6280 million invested in committed projects during the current period, bringing the cumulative investment to RMB 255.4191 million, and a period-end balance of RMB 183.2405 million Overall Use of Raised Funds | Indicator | Amount (RMB 10,000) | | :--- | :--- | | Net Raised Funds | 44,295.03 | | Amount Invested in Committed Projects from Raised Funds in Current Period | 3,262.80 | | Cumulative Amount Invested in Committed Projects from Raised Funds | 25,541.91 | | Cumulative Purchase of Cash Management Products Using Idle Raised Funds in Current Period | 24,300 | | Principal Amount of Cash Management Products Redeemed in Current Period | 27,800 | | Amount of Undue Cash Management Products at End of Current Period | 17,625 | | Remaining Raised Funds (Including Interest Income and Cash Management Products) | 18,324.05 | [Status of Committed Projects Funded by Raised Capital](index=22&type=section&id=%282%29%20Status%20of%20Committed%20Projects%20Funded%20by%20Raised%20Capital) The "Sichuan Enwei Expansion Project" completion date was extended to December 31, 2026, due to product strategy adjustments and new production approvals from the Henan Xinxin Pharmaceutical acquisition, while the Changdu Headquarters Construction Project achieved 100% investment progress Status of Committed Projects Funded by Raised Capital | Committed Investment Project Name | Total Committed Investment from Raised Funds (RMB 10,000) | Cumulative Investment at Period-End (RMB 10,000) | Investment Progress at Period-End | Date Project Reaches Intended Usable State | | :--- | :--- | :--- | :--- | :--- | | Sichuan Enwei Expansion Project | 38,295.03 | 20,642.00 | 53.90% | December 31, 2026 | | Changdu Headquarters Construction Project | 6,000.00 | 4,899.91 | 100.00% | September 20, 2024 | - The completion date for the "Sichuan Enwei Expansion Project" has been extended to **December 31, 2026**, primarily due to the acquisition of Henan Xinxin Pharmaceutical, which added **125 new product approvals** and necessitated a re-evaluation and adjustment of the project's internal investment structure to meet new production line layout and capacity demands[79](index=79&type=chunk) - The Changdu Headquarters Construction Project has a remaining fund balance of **RMB 11.3731 million**, primarily due to cost supervision and control during project construction, and investment income generated from cash management of idle raised funds[79](index=79&type=chunk) [Wealth Management, Derivative Investments, and Entrusted Loans](index=24&type=section&id=VI.%20Wealth%20Management%2C%20Derivative%20Investments%2C%20and%20Entrusted%20Loans) During the reporting period, the company engaged in wealth management activities totaling RMB 271.0474 million, with an outstanding balance of RMB 160.5835 million at period-end, but had no derivative investments or entrusted loans Overview of Wealth Management During the Reporting Period | Specific Type | Amount of Wealth Management Transactions (RMB 10,000) | Undue Balance (RMB 10,000) | | :--- | :--- | :--- | | Bank Wealth Management Products (Raised Funds) | 11,045.40 | 10,016.90 | | Bank Wealth Management Products (Own Funds) | 10,017.89 | 0 | | Brokerage Wealth Management Products (Own Funds) | 6,041.45 | 6,041.45 | | Total | 27,104.74 | 16,058.35 | - The company had no derivative investments or entrusted loans during the reporting period[83](index=83&type=chunk)[84](index=84&type=chunk) [Analysis of Major Holding and Participating Companies](index=25&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) This section analyzes the company's major subsidiaries, Sichuan Enwei Pharmaceutical Co., Ltd. and Enwei (Jiangxi) Pharmaceutical Co., Ltd., detailing their business nature, registered capital, and financial performance during the reporting period Financial Status of Major Subsidiaries | Company Name | Company Type | Main Business | Registered Capital (yuan) | Total Assets (yuan) | Net Profit (yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | | Sichuan Enwei Pharmaceutical Co., Ltd. | Subsidiary | Production, Sales, R&D | 117,713,669.63 | 1,151,588,603.98 | 24,360,159.66 | | Enwei (Jiangxi) Pharmaceutical Co., Ltd. | Subsidiary | Production, Sales | 10,000,000.00 | 69,098,682.76 | 3,790,137.53 | - Sichuan Enwei Pharmaceutical Co., Ltd. is a 100% directly held subsidiary of the joint-stock company, primarily engaged in the research, production, and sales of pharmaceuticals, sanitary products, and disinfectants[87](index=87&type=chunk) - Enwei (Jiangxi) Pharmaceutical Co., Ltd. is a 100% indirectly held subsidiary of the joint-stock company, primarily engaged in the production and sales of mixtures, oral liquids, syrups, and decoctions[88](index=88&type=chunk) [Risks Faced by the Company and Countermeasures](index=25&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces multiple risks, including stringent policy regulation, intense market competition, high R&D investment uncertainty, raw material price volatility, and goodwill impairment, necessitating continuous improvements in quality management, product competitiveness, R&D efficiency, and cost control - Policy and regulatory risk: With the implementation of regulations like the "Drug Administration Law," drug supervision is strengthening, requiring the company to continuously improve its quality management to avoid greater penalties[89](index=89&type=chunk) - Risk of intensified market competition: The company's main products face fierce competition and homogenization issues, necessitating continuous improvement in product quality, technological level, sales models, and marketing network competitiveness, along with reduced production costs[89](index=89&type=chunk) - R&D risk: The pharmaceutical manufacturing industry involves high R&D investment, long cycles, and high uncertainty; if R&D achievements are not effectively commercialized, it will adversely affect the company's competitiveness and profitability[90](index=90&type=chunk) - Raw material price fluctuation risk: Prices of traditional Chinese medicinal materials and active pharmaceutical ingredients are susceptible to fluctuations due to natural climate, market demand, environmental policies, and other factors, which may adversely affect the company's profitability[91](index=91&type=chunk) - Goodwill impairment risk: The acquisition of Jiangxi Enwei in 2017 resulted in goodwill of **RMB 100.5526 million**; if Jiangxi Enwei's future performance falls short of expectations or significant changes occur in the external environment, goodwill impairment may arise[91](index=91&type=chunk) [Registration Form for Research, Communication, and Interview Activities During the Reporting Period](index=26&type=section&id=XI.%20Registration%20Form%20for%20Research%20%2C%20Communication%20%2C%20and%20Interview%20Activities%20During%20the%20Reporting%20Period) During the reporting period, the company engaged with institutional investors through on-site visits and online communications, discussing product information, dividend policies, future business plans, M&A strategies, and progress on shareholder share increase plans - The company conducted on-site research on **January 9 and February 26, 2025**, discussing company products, dividend policies, future business plans, and future M&A plans with institutional investors[92](index=92&type=chunk) - The company conducted online communications via network platforms on **May 8 and May 28, 2025**, discussing 2024 annual and Q1 2025 performance and the progress of shareholder share increase plans with investors[92](index=92&type=chunk) [Corporate Governance, Environment, and Society](index=27&type=section&id=Fourth%20Section%20Corporate%20Governance%2C%20Environment%20and%20Society) This section details the company's governance structure, changes in key personnel, environmental disclosures, and social responsibility initiatives [Changes in Directors, Supervisors, and Senior Management](index=27&type=section&id=I.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Du Changhong, Liu Li, and Yi Li resigned as supervisors, with Du Changhong subsequently elected as an employee representative director due to a job transfer Changes in Directors, Supervisors, and Senior Management | Name | Position Held | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Du Changhong | Chairman of the Supervisory Board | Resignation | May 12, 2025 | Dismissal | | Du Changhong | Employee Representative Director | Elected | May 16, 2025 | Job Transfer | | Liu Li | Supervisor | Resignation | May 12, 2025 | Dismissal | | Yi Li | Supervisor | Resignation | May 12, 2025 | Dismissal | [Profit Distribution and Capital Reserve Conversion to Share Capital During the Reporting Period](index=27&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20During%20the%20Reporting%20Period) The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[96](index=96&type=chunk) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=27&type=section&id=III.%20Implementation%20of%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures implemented during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures implemented during the reporting period[97](index=97&type=chunk) [Environmental Information Disclosure](index=27&type=section&id=IV.%20Environmental%20Information%20Disclosure) Sichuan Enwei Pharmaceutical Co., Ltd., a major subsidiary, is included in the list of enterprises required to disclose environmental information by law and has publicly disclosed it through the designated system - The listed company and its major subsidiary, Sichuan Enwei Pharmaceutical Co., Ltd., are included in the list of enterprises required to disclose environmental information by law[98](index=98&type=chunk) - Sichuan Enwei Pharmaceutical Co., Ltd.'s environmental information disclosure report can be accessed on the Enterprise Environmental Information Disclosure System (Sichuan)[98](index=98&type=chunk) [Social Responsibility](index=27&type=section&id=V.%20Social%20Responsibility) The company actively fulfills its social responsibilities by protecting shareholder and employee rights, promoting environmental sustainability, and engaging in social welfare activities to achieve sustainable development with society [Protection of Shareholder Rights](index=27&type=section&id=%28I%29%20Protection%20of%20Shareholder%20Rights) The company strictly adheres to laws and regulations for transparent, accurate, and timely information disclosure, engaging with investors through various channels and ensuring complete profit distribution procedures to safeguard minority shareholder rights - The company strictly adheres to legal and regulatory requirements for truthful, accurate, complete, timely, and fair information disclosure, safeguarding the interests of all investors[99](index=99&type=chunk) - The company communicates with investors through various channels, including investor hotlines, interactive platforms, collective reception days, and performance briefings[99](index=99&type=chunk) - The company strictly implements its profit distribution policy, with clear dividend standards and ratios, complete decision-making procedures, and provides online voting, to fully protect the legitimate rights and interests of minority shareholders[99](index=99&type=chunk) [Protection of Employee Rights](index=28&type=section&id=%28II%29%20Protection%20of%20Employee%20Rights) The company rigorously protects employee rights by providing a safe and comfortable working environment through technological improvements and automation, offering good office, dining, and accommodation facilities, regular health check-ups, and cultural activities to ensure employee well-being - The company strictly adheres to relevant laws and standards to protect employees' legitimate rights and interests, providing a good working environment through technological improvements, equipment upgrades, and increased automation[100](index=100&type=chunk) - The company provides employees with comfortable office, dining, and accommodation environments, arranges regular health check-ups, and organizes various cultural and sports activities to enrich employee life and ensure their physical and mental well-being[100](index=100&type=chunk) [Environmental Protection](index=28&type=section&id=%28III%29%20Environmental%20Protection) As a pharmaceutical manufacturer, the company prioritizes environmental protection, strictly complying with national environmental laws, actively practicing green and low-carbon principles, and continuously upgrading its technology and equipment to achieve harmonious coexistence with the community and environment - The company places high importance on environmental protection, strictly complying with national environmental laws and regulations, and actively practicing green and low-carbon principles in its production and operations[101](index=101&type=chunk) - The company strengthens technological and equipment improvements, continuously promotes green and environmentally friendly technical upgrades, achieving harmonious coexistence and sustainable development with the community and environment[101](index=101&type=chunk) [Social Welfare](index=28&type=section&id=%28IV%29%20Social%20Welfare) The company consistently balances business development with social responsibility, actively responding to national policies, strengthening ties with local governments and charitable organizations, and undertaking various public welfare activities during the reporting period to foster corporate and societal prosperity - The company consistently prioritizes social welfare, adhering to the philosophy of balancing corporate development with social responsibility, and actively responding to national policy calls[102](index=102&type=chunk) - During the reporting period, the company actively carried out multiple public welfare activities, striving to promote the co-prosperity of the enterprise and society[102](index=102&type=chunk) [Significant Matters](index=29&type=section&id=Fifth%20Section%20Significant%20Matters) This section covers critical events and disclosures, including commitments, related party transactions, litigation, and other material issues affecting the company [Commitments](index=29&type=section&id=I.%20Commitments) During the reporting period, the company had no unfulfilled or overdue commitments from its actual controllers, shareholders, related parties, acquirers, or the company itself - During the reporting period, the company had no commitments that were fulfilled or overdue by the end of the reporting period from its actual controllers, shareholders, related parties, acquirers, or the company itself[104](index=104&type=chunk) [Non-Operating Funds Occupied by Controlling Shareholders and Other Related Parties](index=29&type=section&id=II.%20Non-Operating%20Funds%20Occupied%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties) During the reporting period, there were no instances of non-operating funds being occupied by controlling shareholders or other related parties of the listed company - During the reporting period, there were no instances of non-operating funds being occupied by controlling shareholders or other related parties of the listed company[105](index=105&type=chunk) [Irregular External Guarantees](index=29&type=section&id=III.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[106](index=106&type=chunk) [Appointment and Dismissal of Accounting Firms](index=29&type=section&id=IV.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual financial report was not audited - The company's semi-annual report was not audited[107](index=107&type=chunk) [Litigation Matters](index=29&type=section&id=VIII.%20Litigation%20Matters) The company had no significant litigation or arbitration matters during the reporting period - The company had no significant litigation or arbitration matters during the reporting period[109](index=109&type=chunk) [Penalties and Rectification](index=30&type=section&id=IX.%20Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[110](index=110&type=chunk) [Significant Related Party Transactions](index=30&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company engaged in routine related party transactions with Jilin Enwei Ruibang Pharmaceutical Co., Ltd., purchasing goods worth RMB 3.3137 million, which did not exceed the approved limit, and had no related party transactions involving asset/equity acquisition/disposal, joint investments, or related party debts Related Party Transactions for Purchase and Sale of Goods | Related Party | Related Party Transaction Content | Related Party Transaction Amount (RMB 10,000) | Approved Transaction Limit (RMB 10,000) | Exceeded Approved Limit | | :--- | :--- | :--- | :--- | :--- | | Jilin Enwei Ruibang Pharmaceutical Co., Ltd. | Purchase of Goods | 331.37 | 500.00 | No | - During the reporting period, the company had no related party transactions involving asset or equity acquisition/disposal, joint external investments, or related party creditor-debtor relationships[112](index=112&type=chunk)[113](index=113&type=chunk)[114](index=114&type=chunk) [Significant Contracts and Their Performance](index=31&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) The company had no significant entrustment, contracting, or leasing matters, nor any major guarantees or daily operating contracts with a significant impact on its profit or loss during the reporting period - The company had no entrustment, contracting, or leasing matters during the reporting period[118](index=118&type=chunk)[119](index=119&type=chunk)[120](index=120&type=chunk) - The company had no significant guarantee situations during the reporting period[122](index=122&type=chunk) - The company had no daily operating contracts with a significant impact during the reporting period[124](index=124&type=chunk) [Share Changes and Shareholder Information](index=33&type=section&id=Sixth%20Section%20Share%20Changes%20and%20Shareholder%20Information) This section outlines changes in the company's share capital, shareholder structure, and the shareholdings of directors, supervisors, and senior management [Share Changes](index=33&type=section&id=I.%20Share%20Changes) During the reporting period, restricted shares increased by 49,555 shares, and unrestricted shares decreased by 49,555 shares, primarily due to the transfer of Chairman Xue Yongjiang's shares from partnership liquidation to his personal name, with 75% of these shares locked Share Changes | Share Class | Number Before Change (shares) | Increase/Decrease in This Change (shares) | Number After Change (shares) | | :--- | :--- | :--- | :--- | | I. Restricted Shares | 69,936,699 | +49,555 | 69,986,254 | | Of which: Shares Held by Domestic Natural Persons | 146,515 | +49,555 | 196,070 | | II. Unrestricted Shares | 32,955,188 | -49,555 | 32,905,633 | | Of which: RMB Ordinary Shares | 32,955,188 | -49,555 | 32,905,633 | | III. Total Shares | 102,891,887 | 0 | 102,891,887 | - The share change resulted from the liquidation of three partnerships, including Changdu Changwei, where Chairman Xue Yongjiang's total of **66,073 Enwei Pharmaceutical shares** obtained from the liquidation were transferred to his personal name via non-trading transfer, with **75% of these shares locked by the Shenzhen Stock Exchange**[131](index=131&type=chunk) [Number of Shareholders and Shareholding Status](index=34&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) At the end of the reporting period, the company had 7,348 common shareholders, with Chengdu Enwei Investment (Group) Co., Ltd. as the largest shareholder at 28.90%, and the actual controllers collectively indirectly controlling 68.77% of the equity, while the company's repurchased shares account for 1.76% for future employee incentive plans - At the end of the reporting period, the total number of common shareholders was **7,348**[136](index=136&type=chunk) Shareholding Status of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at End of Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Pledged, Marked, or Frozen Shares (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Chengdu Enwei Investment (Group) Co., Ltd. | Domestic Non-State-Owned Legal Person | 28.90% | 29,733,200 | 29,733,200 | 20,940,000 | | Chengdu Jiewei Enterprise Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 13.38% | 13,763,936 | 12,884,140 | 6,000,000 | | Chengdu Ruijinheng Enterprise Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 12.52% | 12,884,140 | 12,884,140 | 9,330,836 | | Chengdu Zehong Enterprise Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 12.52% | 12,884,140 | 12,884,140 | 7,730,000 | - The company's actual controllers, Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong, collectively indirectly control **68.77% of the company's equity** and corresponding voting rights through Enwei Group, Chengdu Jiewei, Chengdu Ruijinheng, Chengdu Zehong, and Changdu Jieweite[137](index=137&type=chunk) - The company's special repurchase securities account holds **1,815,526 treasury shares**, accounting for **1.76% of the company's total shares**, planned for implementing employee stock ownership plans or equity incentives[137](index=137&type=chunk) [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=36&type=section&id=IV.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Mr. Xue Yongjiang, the company's Chairman and CEO, increased his shareholding by 66,073 shares, bringing his total shares held at period-end to 66,073 shares Changes in Shareholdings of Directors, Supervisors, and Senior Management | Name | Position | Employment Status | Shares Held at Beginning of Period (shares) | Number of Shares Increased in Current Period (shares) | Shares Held at End of Period (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Xue Yongjiang | Chairman, CEO | Current | 0 | 66,073 | 66,073 | [Changes in Controlling Shareholder or Actual Controller](index=36&type=section&id=V.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[140](index=140&type=chunk) - The company's actual controller remained unchanged during the reporting period[140](index=140&type=chunk) [Bond-Related Information](index=37&type=section&id=Seventh%20Section%20Bond-Related%20Information) This section provides details on any bond-related activities or instruments issued by the company during the reporting period [Bond-Related Information](index=37&type=section&id=Bond-Related%20Information) The company had no bond-related situations during the reporting period - The company had no bond-related situations during the reporting period[143](index=143&type=chunk) [Financial Report](index=38&type=section&id=Eighth%20Section%20Financial%20Report) This section contains the complete audited or unaudited financial statements, including balance sheets, income statements, cash flow statements, and detailed notes [Audit Report](index=38&type=section&id=I.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[145](index=145&type=chunk) [Financial Statements](index=38&type=section&id=II.%20Financial%20Statements) This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025, offering a comprehensive view of its financial position, operating results, and cash flows Key Data from Consolidated Balance Sheet (Period-End Balance) | Item | Period-End Balance (yuan) | Beginning Balance (yuan) | | :--- | :--- | :--- | | Total Assets | 1,515,984,797.29 | 1,504,528,918.05 | | Total Liabilities | 433,105,761.15 | 446,857,834.56 | | Total Equity Attributable to Parent Company Owners | 1,082,879,036.14 | 1,057,671,083.49 | Key Data from Consolidated Income Statement (Current Period Amount) | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 449,221,452.75 | 388,149,545.27 | | Operating Profit | 45,901,404.70 | 23,349,097.61 | | Total Profit | 45,729,439.39 | 22,937,854.76 | | Net Profit | 38,344,181.25 | 17,934,442.73 | | Net Profit Attributable to Parent Company Shareholders | 38,344,181.25 | 17,934,442.73 | | Basic Earnings Per Share | 0.3845 | 0.1769 | | Diluted Earnings Per Share | 0.3838 | 0.1760 | Key Data from Consolidated Cash Flow Statement (Current Period Amount) | Item | H1 2025 (yuan) | H1 2024 (yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 75,182,160.82 | 90,270,973.06 | | Net Cash Flow from Investing Activities | -38,767,462.92 | 30,785,409.38 | | Net Cash Flow from Financing Activities | -25,580,789.63 | 96,539,637.29 | | Net Increase in Cash and Cash Equivalents | 10,833,882.85 | 217,596,060.12 | [Company Basic Information](index=55&type=section&id=III.%20Company%20Basic%20Information) This section details Enwei Pharmaceutical Co., Ltd.'s establishment history, capital changes, equity structure, and ultimate control, noting its establishment in 2005, transformation into a joint-stock company in 2018, IPO in 2022, and the collective indirect control of 68.77% equity by Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong as of June 30, 2025 - Enwei Pharmaceutical Co., Ltd. was established in **May 2005**, underwent multiple changes in registered capital and equity transfers, was restructured into a joint-stock company in **2018**, and conducted its initial public offering in **2022**[179](index=179&type=chunk)[180](index=180&type=chunk)[181](index=181&type=chunk)[182](index=182&type=chunk)[183](index=183&type=chunk)[184](index=184&type=chunk)[185](index=185&type=chunk)[186](index=186&type=chunk) Company Share Capital and Equity Structure as of June 30, 2025 | Shareholder | Capital Contribution (yuan) | Contribution Percentage (%) | | :--- | :--- | :--- | | Chengdu Enwei Investment (Group) Co., Ltd. | 29,733,200.00 | 28.90 | | Chengdu Ruijinheng Enterprise Management Co., Ltd. | 12,884,140.00 | 12.52 | | Chengdu Zehong Enterprise Management Co., Ltd. | 12,884,140.00 | 12.52 | | Chengdu Jiewei Enterprise Management Co., Ltd. | 13,763,936.00 | 13.38 | | Changdu Jieweite Enterprise Management Co., Ltd. | 1,496,652.00 | 1.45 | | Publicly Issued Shares | 32,129,819.00 | 31.23 | | Total | 102,891,887.00 | 100.00 | - Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong collectively indirectly control **68.77% of the company's equity** and corresponding voting rights through Enwei Group, Chengdu Jiewei, Chengdu Zehong, Chengdu Ruijinheng, and Changdu Jieweite, serving as the company's actual controllers[188](index=188&type=chunk) [Basis of Financial Statement Preparation](index=58&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) The company's financial statements are prepared in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance and relevant CSRC regulations, based on a going concern assumption, with no issues affecting its ability to continue as a going concern identified - The company's financial statements are prepared based on actual transactions and events, in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance, their application guidelines, interpretations, and other relevant regulations, as well as the disclosure requirements of the China Securities Regulatory Commission's "Reporting Rules for Information Disclosure by Companies Issuing Securities No. 15—General Provisions for Financial Reports" (Revised 2023)[190](index=190&type=chunk) - The company assessed its ability to continue as a going concern for 12 months from the end of the reporting period, finding no matters affecting its going concern ability, thus preparing financial statements on a going concern basis is reasonable[191](index=191&type=chunk) [Significant Accounting Policies and Estimates](index=58&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's significant accounting policies and estimates for financial statement preparation, covering financial instruments, inventories, long-term equity investments, fixed assets, intangible assets, revenue recognition, government grants, deferred tax assets/liabilities, and leases, ensuring accuracy and compliance - The specific accounting policies and estimates formulated by the company based on its actual production and operating characteristics include operating cycle, recognition and measurement of bad debt provisions for receivables, measurement of inventory issued, classification and depreciation methods for fixed assets, amortization of intangible assets, capitalization conditions for R&D expenses, and revenue recognition and measurement[192](index=192&type=chunk) - The company's financial assets are classified upon initial recognition as: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss[207](index=207&type=chunk) - The company recognizes revenue when it satisfies a performance obligation in a contract, which is when the customer obtains control of the related goods or services[270](index=270&type=chunk) - The company's government grants include asset-related government grants and income-related government grants, which are either offset against the carrying amount of related assets or recognized as deferred income, or recognized as deferred income or included in current profit and loss, respectively[278](index=278&type=chunk)[279](index=279&type=chunk) [Taxation](index=79&type=section&id=VI.%20Taxation) This section lists the main tax categories and rates for the company and its subsidiaries, including VAT, urban maintenance and construction tax, and corporate income tax, with some entities benefiting from Western Development corporate income tax incentives (15% rate) or small and micro-enterprise income tax incentives (20% rate) Main Tax Categories and Rates | Tax Category | Tax Base | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax | Value-added amount from sales of goods and provision of taxable services | 13%, 9%, 6%, 5%, 3% | | Urban Maintenance and Construction Tax | Actual amount of turnover tax paid | 7%, 5% | | Corporate Income Tax | Taxable Income | 15%, 20%, 25% | Taxable Entities with Different Corporate Income Tax Rates | Taxable Entity Name | Income Tax Rate | | :--- | :--- | | The Company | 15% | | Sichuan Enwei Pharmaceutical Co., Ltd. | 15% | | Enwei (Jiangxi) Pharmaceutical Co., Ltd. | 25% | | Chengdu Jieeryin Pharmaceutical Technology Co., Ltd. | 20% | - The company and its subsidiary, Sichuan Enwei Pharmaceutical Co., Ltd., qualify for the Western Development policy, paying corporate income tax at a **15% rate**; some subsidiaries qualify for small and micro-enterprise preferential policies, paying corporate income tax at a **20% rate**[295](index=295&type=chunk)[296](index=296&type=chunk)[297](index=297&type=chunk) [Notes to Consolidated Financial Statement Items](index=80&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes for each item in the consolidated financial statements, including cash and cash equivalents, financial assets held for trading, accounts receivable, inventories, long-term equity investments, fixed assets, construction in progress, intangible assets, goodwill, long-term deferred expenses, deferred tax assets/liabilities, accounts payable, other payables, contract liabilities, employee benefits payable, taxes payable, long-term borrowings, lease liabilities, deferred income, share capital, capital reserves, treasury shares, surplus reserves, undistributed profits, operating revenue and costs, taxes and surcharges, administrative expenses, selling expenses, R&D expenses, financial expenses, other income, investment income, credit impairment losses, asset impairment losses, gains from asset disposal, non-operating income, non-operating expenses, income tax expenses, cash flow statement items, notes to statement of changes in owners' equity, foreign currency monetary items, and leases Composition of Cash and Cash Equivalents | Item | Period-End Balance (yuan) | Beginning Balance (yuan) | | :--- | :--- | :--- | | Cash on Hand | 10,401.41 | 23,654.44 | | Bank Deposits | 282,806,749.80 | 267,776,323.79 | | Other Cash and Cash Equivalents | 77,273,583.69 | 102,474,515.36 | | Total | 360,090,734.90 | 370,274,493.59 | Disclosure of Accounts Receivable Aging (Period-End Book Balance) | Aging | Period-End Book Balance (yuan) | | :--- | :--- | | Within 1 year (inclusive) | 179,473,788.53 | | 1 to 2 years | 888,089.34 | | 2 to 3 years | 416,213.54 | | Over 3 years | 425,349.48 | | Total | 181,203,440.89 | Inventory Classification (Period-End Book Value) | Item | Book Value (yuan) | | :--- | :--- | | Raw Materials | 28,642,496.40 | | Work in Progress | 15,006,432.69 | | Finished Goods Inventory | 57,852,439.04 | | Goods in Transit | 3,403,069.91 | | Packaging Materials and Low-Value Consumables | 7,985,734.29 | | Total | 112,890,172.33 | Construction in Progress (Period-End Book Value) | Item | Book Value (yuan) | | :--- | :--- | | Production Workshop Renovation | 24,790,429.69 | | Sub-packaging Workshop Production Line Renovation | 11,263,658.38 | | New 106 Intelligent Automated Warehouse | 8,341,632.69 | | Total | 54,845,564.79 | Operating Revenue and Operating Cost (Current Period Amount) | Item | Revenue (yuan) | Cost (yuan) | | :--- | :--- | :--- | | Main Business | 447,248,530.38 | 227,467,248.61 | | Other Businesses | 1,972,922.37 | 1,198,472.10 | | Total | 449,221,452.75 | 228,665,720.71 | [Research and Development Expenses](index=116&type=section&id=VIII.%20Research%20and%20Development%20Expenses) The company's total R&D expenses for the reporting period amounted to 2,538,865.32 yuan, a 24.61% year-on-year decrease, primarily comprising direct labor, share-based payments, depreciation, and direct material inputs Composition of R&D Expenses | Item | Amount in Current Period (yuan) | Amount in Prior Period (yuan) | | :--- | :--- | :--- | | Direct Labor | 1,703,070.75 | 1,779,861.29 | | Share-Based Payment | 156,187.34 | 550,969.14 | | Depreciation | 276,536.16 | 334,973.52 | | Direct Material Input | 135,928.97 | 52,028.45 | | Other | 267,142.10 | 95,605.08 | | Total | 2,538,865.32 | 3,367,770.05 | | Of which: Expensed R&D Expenses | 2,538,865.32 | 3,367,770.05 | [Changes in Consolidation Scope](index=116&type=section&id=IX.%20Changes%20in%20Consolidation%20Scope) The company had no transactions or events resulting in the loss of control over subsidiaries, nor any other changes in the consolidation scope during the reporting period - The company had no transactions or events resulting in the loss of control over subsidiaries during the reporting period[468](index=468&type=chunk) - The company had no other changes in the consolidation scope during the reporting period (e.g., establishment of new subsidiaries, liquidation of subsidiaries)[469](index=469&type=chunk) [Interests in Other Entities](index=117&type=section&id=X.%20Interests%20in%20Other%20Entities) This section details the company's enterprise group structure, including first-level and second-level subsidiaries, specifying each subsidiary's registered capital, main operating location, business nature, shareholding percentage, and acquisition method Composition of the Enterprise Group | Subsidiary Name | Registered Capital (yuan) | Main Operating Location | Business Nature | Shareholding Percentage (Direct) | Shareholding Percentage (Indirect) | Acquisition Method | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Sichuan Enwei Pharmaceutical Co., Ltd. | 117,713,669.63 | Chengdu City | Production, Sales, R&D | 100.00% | | Business Combination Under Common Control | | Chengdu Jieeryin Pharmaceutical Technology Co., Ltd. | 10,000,000.00 | Chengdu City | Sales, Development | 100.00% | | Investment Establishment | | Enwei (Zhengzhou) Pharmaceutical Technology Co., Ltd. | 10,000,000.00 | Zhengzhou City | Production, Sales | 50.00% | 50.00% | Investment Establishment | | Enwei (Jiangxi) Pharmaceutical Co., Ltd. | 10,000,000.00 | Ji'an City | Production, Sales, R&D | | 100.00% | Business Combination Not Under Common Control | | Henan Xinxin Pharmaceutical Co., Ltd. | 50,000,000.00 | Zhengzhou City | Production, Sales | | 100.00% | Acquisition Merger | [Government Grants](index=118&type=section&id=XI.%20Government%20Grants) This section discloses the company's government grant-related liability items for the reporting period, primarily deferred income, with a period-end balance of 8,799,773.31 yuan and 1,157,656.20 yuan transferred to other income in the current period Liability Items Involving Government Grants | Account Title | Beginning Balance (yuan) | Amount Transferred to Other Income in Current Period (yuan) | Period-End Balance (yuan) | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 9,957,429.51 | 1,157,656.20 | 8,799,773.31 | Asset-related | Government Grants Recognized in Current Profit and Loss | Account Title | Amount in Current Period (yuan) | Amount in Prior Period (yuan) | | :--- | :--- | :--- | | Other Income | 459,113.69 | 691,474.99 | [Risks Related to Financial Instruments](index=118&type=section&id=XII.%20Risks%20Related%20to%20Financial%20Instruments) The company faces market risks (exchange rate, interest rate, price), credit risk, and liquidity risk, which it manages through customer credit limit reviews, bad debt provisions, monitoring bank borrowings, and financing negotiations - Market risks include exchange rate risk (subsidiary Sichuan Enwei Pharmaceutical has some foreign currency sales, but the impact is minor), interest rate risk (interest-bearing debts such as bank borrowings), and price risk (raw material procurement and product sales)[476](index=476&type=chunk)[477](index=477&type=chunk)[478](index=478&type=chunk) - Credit risk primarily arises from the failure of a counterparty to fulfill its obligations, which the company mitigates by reviewing customer credit limits, monitoring procedures, and making provisions for bad debts[479](index=479&type=chunk) - Liquidity risk refers to the risk of being unable to meet financial obligations, which the company manages by ensuring sufficient cash liquidity, regularly analyzing debt structure and maturity, monitoring bank borrowings, and engaging in financing negotiations[482](index=482&type=chunk) [Fair Value Disclosure](index=119&type=section&id=XIII.%20Fair%20Value%20Disclosure) This section discloses the period-end fair value of the company's assets and liabilities measured at fair value, categorized by fair value hierarchy, noting that receivables financing has a fair value close to its carrying amount due to short remaining maturity, and Level 3 non-current financial assets (e.g., unlisted equity) use cost as the best estimate of fair value Period-End Fair Value of Assets and Liabilities Measured at Fair Value | Item | Level 2 Fair Value Measurement (yuan) | Level 3 Fair Value Measurement (yuan) | Total (yuan) | | :--- | :--- | :--- | :--- | | Financial Assets Held for Trading | 160,583,535.19 | 14,400,000.00 | 174,983,535.19 | | Of which: Equity Instrument Investments | | 14,400,000.00 | 14,400,000.00 | | Of which: Wealth Management Products | 160,583,535.19 | | 160,583,535.19 | | Other Debt Investments | 110,157,392.47 | | 110,157,392.47 | - For receivables financing measured at fair value, the fair value is close to the carrying amount due to its short remaining maturity[486](index=486&type=chunk) - For Level 3 fair value measured non-current financial assets (e.g., unlisted equity), cost is used as the best estimate of fair value due to the low equity holding percentage, lack of significant influence, and absence of observable market prices[487](index=487&type=chunk) [Related Parties and Related Party Transactions](index=120&type=section&id=XIV.%20Related%20Parties%20and%20Related%20Party%20Transactions) This section identifies Chengdu Enwei Investment (Group) Co., Ltd. as the parent company and Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong as the ultimate controlling parties, disclosing a related party transaction for goods procurement with Jilin Enwei Ruibang Pharmaceutical Co., Ltd. amounting to 3,313,737.08 yuan, and total key management personnel compensation of 1,979,747.94 yuan Information on the Company's Parent Company | Parent Company Name | Registered Address | Business Nature | Registered Capital | Shareholding Percentage | Voting Rights Percentage | | :--- | :--- | :--- | :--- | :--- | :--- | | Chengdu Enwei Investment (Group) Co., Ltd. | Chengdu City | Investment, Sales | RMB 50.00 million | 28.90% | 28.90% | - The ultimate controlling parties of the company are Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong, who collectivel

法定代表人： 薛永江 主管会计工作负责人： 胡大伟 会计机构负责人：甯惠 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：恩威医药股份有限公司 | 单位：万元 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算的 | 2025年期初占用资金 | 2025半年度占用累计发 | 2025年半年度占用资 | 2025年半年度偿 | 2025年半年度期末占 | 占用形成原 | 占用性质 | | | | 的关联关系 | 会计科目 | 余额 | 生金额（不含利息） | 金的利息(如有） | 还累计发生金额 | 用资金余额 | 因 | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | | ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-038 恩威医药股份有限公司董事会 募集资金年度存放与使用情况的专项报告 （2025 年半年度） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第2号——上市公司 募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》及《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关 法律、法规和规范性文件规定，恩威医药股份有限公司（以下简称"公司"或"本公 司"）董事会编制了2025年半年度募集资金存放与实际使用情况的专项报告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，每股面 值 1 ...

关于公司部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 证券代码：301331 证券简称：恩威医药 公告编号：2025-039 恩威医药股份有限公司 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A股）股票 17,540,000 股，每股面 值 1.00 元，发行价格为人民币 29.80 元/股。本次募集资金总额为人民币 522,692,000.00 元，扣除发行费用（不含增值税）人民币 79,741,650.79 元后，实 际募集资金净额为人民币 442,950,349.21 元。 上述募集资金已于 2022 年 9 月 13 日划至公司募集资金专项账户，信永中和 会计师事务所（特殊普通合伙）已对公司募集资金的到位情况进行了审验，并于 当日出具《验资报告》（XYZH/2022CDAA30417）。公司已与存放募集资金的 商业银行、保荐人签署了募集资金监管协议。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-040 恩威医药股份有限公司 2025 年 8 月 26 日 （https://ir.p5w.net）参与本次半年度业绩说明会。 出席本次说明会的人员有：公司董事长兼首席执行官薛永江、副总裁兼董事会秘书、 财务总监胡大伟、独立董事刘娅、保荐代表人石坡。 为充分尊重投资者、提升交流的针对性，现就公司 2025 年半年度网上业绩说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 9 月 3 日（星期三）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专 题页面。公司将在 2025 年半年度网上业绩说明会上，对投资者普遍关注的问题进行回 答。 欢迎广大投资者积极参与本次网上业绩说明会。 恩威医药股份有限公司董事会 关于举行 2025 年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"）定于 2025 年 9 月 3 日（星期三）下午 15：00-16：30 ...